John Patrick Genn Net Worth

What's John Genn's mailing address?

John's mailing address filed with the SEC is C/O CELLECTAR BIOSCIENCES, INC., 3301 AGRICULTURE DRIVE, MADISON, WI, 53716.

Insiders trading at Cellectar Biosciences Inc

Over the last 10 years, insiders at Cellectar Biosciences Inc have traded over $1,263,511 worth of Cellectar Biosciences Inc stock and bought 1,917,793 units worth $3,966,598 . The most active insiders traders include Austin W & Greenhouse David..., Investment Company, Inc. Awm a John Neis. On average, Cellectar Biosciences Inc executives and independent directors trade stock every 50 days with the average trade being worth of $126,821. The most recent stock trade was executed by Douglas J Swirsky on 14 September 2021, trading 25,000 units of CLRB stock currently worth $26,000.

What does Cellectar Biosciences Inc do?

cellectar biosciences is developing phospholipid drug conjugates (pdcs) designed to provide cancer targeted delivery of diverse oncologic payloads to a broad range of cancers and cancer stem cells. cellectar's pdc platform is based on the company's proprietary phospholipid ether analogs. these novel small-molecules have demonstrated highly selective uptake and retention in a broad range of cancers. cellectar's pdc pipeline includes product candidates for cancer therapy and cancer diagnostic imaging. the company's lead therapeutic pdc, clr 131, utilizes iodine-131, a cytotoxic radioisotope, as its payload. clr 131 has been designated as an orphan drug by the us fda and is currently being evaluated in a phase 1 clinical study in patients with relapsed or refractory multiple myeloma and a phase 2 clinical study to assess efficacy in a range of b-cell malignancies. the company is also developing proprietary pdcs for targeted delivery of chemotherapeutics and has several preclinical stage p

Cellectar Biosciences Inc executives and stock owners

Cellectar Biosciences Inc executives and other stock owners filed with the SEC include:

• James Caruso,
  President, Chief Executive Officer, Director
• James V. Caruso,
  Pres, CEO & Director
• Jarrod Longcor,
  Chief Business Officer
• Jarrod Longcor,
  Chief Operating Officer
• John Friend,
  Vice President, Chief Medical Officer
• Dov Elefant,
  Chief Financial Officer, Vice President
• Douglas Swirsky,
  Independent Chairman of the Board
• John Neis,
  Independent Director
• Stefan Loren,
  Independent Director
• Stephen Hill,
  Independent Director
• Frederick Driscoll,
  Independent Director
• Gregory J. Lynch Esq.,
  Sec.
• Dr. Laurence Reilly L.L.M., LL.M, M.D., MBChB,
  Interim Chief Medical Officer
• Chad J. Kolean CPA, CPA,
  Chief Financial Officer
• Richard Hertzberg,
  
• Brian M Posner,
  Chief Financial Officer
• Igor D Grachev,
  Chief Medical Officer
• Jamey P Weichert,
  Chief Scientific Officer
• Paul L Berns,
  Director
• Investment Company, Inc. Awm,
  10% owner
• John Patrick Genn,
  VP of Business Development
• Cameron Szakacs,
  VP of Clinical Development
• Simon Pedder,
  President and CEO
• Austin W & Greenhouse David...,
  10% owner
• Asher Chanan Khan,
  Director
• Chad J Kolean,
  Chief Financial Officer
• Darrell Shane Lea,
  Chief Commercial Officer
• Andrei Shustov,
  Senior Vice President, Medical